Equities researchers at Dougherty & Co initiated coverage on shares of Second Sight Medical Products (NASDAQ:EYES) in a note issued to investors on Friday, The Fly reports. The brokerage set a “buy” rating on the medical device company’s stock.
Other equities analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of Second Sight Medical Products from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a research note on Wednesday, November 20th. ValuEngine raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a report on Tuesday, December 3rd.
Shares of EYES stock opened at $0.77 on Friday. The company has a quick ratio of 2.66, a current ratio of 2.83 and a debt-to-equity ratio of 0.17. Second Sight Medical Products has a twelve month low of $0.63 and a twelve month high of $1.20. The company has a market cap of $98.43 million, a P/E ratio of -1.49 and a beta of 2.32. The business has a fifty day simple moving average of $0.83 and a 200 day simple moving average of $0.81.
Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Thursday, November 14th. The medical device company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). Second Sight Medical Products had a negative return on equity of 201.34% and a negative net margin of 743.86%. The business had revenue of $0.47 million for the quarter, compared to analyst estimates of $0.94 million. As a group, equities research analysts anticipate that Second Sight Medical Products will post -0.29 earnings per share for the current fiscal year.
Second Sight Medical Products Company Profile
Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury.
Featured Article: Current Ratio
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.